Skip to main content

Table 2 MYC, FBXW7 and TP53 mRNA expression levels and clinicopathological factors of 33 gastric cancer patients

From: MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer

  n (%) MYC p- value FBXW7 p- value TP53 p- value
   Median ± IQR   Median ± IQR   Median ± IQR  
Age (y) (mean ± SD)        
>50 (65.3 ± 9.1) 19 (57.6%) 2.04 ± 1.35 0.8873 0.55 ± 0.37 0.9247 0.86 ± 0.62 0.7409
≤50 (42.1 ± 8.2) 14 (42.4%) 1.44 ± 4.88   0.53 ± 0.50   0.94 ± 1.65  
Gender        
Male 15 (45.5%) 2.01 ± 1.01 0.4065 0.53 ± 0.22 0.6353 0.89 ± 0.58 0.8125
Female 18 (54.5%) 1.67 ± 2.03   0.56 ± 0.56   0.87 ± 0.69  
Histopathology        
Intestinal 22 (66.7%) 2.06 ± 0.99 0.3525 0.53 ± 0.16 0.1391 0.81 ±0.78 0.3311
Diffuse 11 (33.3%) 1.40 ± 2.32   0.77 ±0.74   0.94 ± 0.38  
Depth of tumor invasion        
T1 6 (18.2%) 0.89 ± 0.47 0.0857 0.88 ± 0.58 0.0678 0.85 ± 0.15 0.7069
T2-T4 27 (81.8%) 2.08 ± 1.42   0.53 ± 0.43   0.91 ± 0.79  
Lymph node metastasis        
Absent 13 (39.4%) 0.98 ± 1.09 0.0225* 0.68 ± 0.36 0.0238* 0.84 ± 0.44 0.6121
Present 20 (60.6%) 2.10 ± 2.20   0.46 ± 0.38   0.94 ± 0.79  
Stage        
I-II 18 (54.5%) 1.39 ± 1.23 0.0362* 0.57 ± 0.38 0.0380* 0.83 ± 0.55 0.0892
III-IV 15 (45.5%) 2.41 ± 2.79   0.34 ± 0.45   0.96 ± 1.19  
MYC IHC        
Positive 20 (60.6%) 2.18 ± 1.59 0.0022* 0.53 ± 0.32 0.4090 0.81 ± 0.57 0.1372
Negative 13 (39.4%) 0.89 ± 0.85   0.58 ± 0.53   0.99 ± 0.90  
p53 IHC        
Positive 7 (21.2%) 4.25 ± 6.53 0.0891 0.64 ± 0.68 0.9203 1.06 ± 0.83 0.2937
Negative 26 (78.8%) 2.00 ± 1.44   0.55 ± 0.35   0.87 ± 0.60  
  1. *p < 0.05; IQR: interquartile range.